ornithine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
An, X; Coonrod, SA; Li, F; Li, T; Liu, X; Miao, L; Muth, A; Qin, H; Thompson, PR; Xu, B; Zhang, X | 1 |
Forget, SM; Goralski, KB; Hall, SR; Jakeman, DL; Kerr, RG; MacLeod, JM; Overy, DP; Robertson, AW | 1 |
2 other study(ies) available for ornithine and ER-Negative PR-Negative HER2-Negative Breast Cancer
Article | Year |
---|---|
PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; HEK293 Cells; Humans; Hydrolases; MAP Kinase Kinase 1; MAP Kinase Signaling System; Matrix Metalloproteinase 2; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Ornithine; Protein-Arginine Deiminase Type 1; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Isolation of a jadomycin incorporating L-ornithine, analysis of antimicrobial activity and jadomycin reactive oxygen species (ROS) generation in MDA-MB-231 breast cancer cells.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Isoquinolines; Microbial Sensitivity Tests; Ornithine; Reactive Oxygen Species; Staphylococcus; Streptomyces; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2018 |